Novartis

Views & Analysis

R&D Roundup: Novartis pipeline, CRISPR funding and Opdivo di...

Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline.

News

EU regulators accept Novartis' triple asthma combo

European regulators have accepted Novartis’ filing for a triple combination therapy for asthma known as QVM149, triggering payments to development partners Vectura and Sosei.

News

Novartis shows off pipeline - including 25 potential blockbu...

Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline.

News

Takeda to sell dry eye drug to Novartis for up to $5.3bn

Takeda has announced it is to sell the dry eye drug Xiidra to Novartis, and a surgical patch to Johnson & Johnson, for a potential total of $5.7 billion as it seeks to pay off debts fol

Views & Analysis

Collaborating to fight NASH

Eric Hughes, Global Development Unit head at Novartis for Immunology, Hepatology & Dermatology, believes that collaboration is going to be key to finally finding a treatment for non

News